Federal Reserve's monetary policy and inflation trends, influencing borrowing costs and investor sentiment towards growth-oriented biotech companies.

Overall market risk appetite, affected by global economic outlook and volatility, which impacts investments in higher-risk biotechnology stocks like Akebia.

Healthcare industry funding and evolving regulatory environment for drug approvals and reimbursement policies, crucial for the commercial success of Akebia's kidney disease therapeutics.